par Liefferinckx, Claire 
;Cremer, Anneline ;Franchimont, Denis
Référence Current opinion in pharmacology, 55, page (82-89)
Publication Publié, 2020-12-01
;Cremer, Anneline ;Franchimont, Denis Référence Current opinion in pharmacology, 55, page (82-89)
Publication Publié, 2020-12-01
Article révisé par les pairs
| Résumé : | Inflammatory bowel disease patients do not all respond to biological treatment since several patients will initially respond but will lose response or develop side effects over time. In such cases, a switch from one biologic to another offers a valuable clinical solution. This requires to evaluate both patient and drug profiles in combination with the reason(s) for switching in order to adequately select the second-line biologic. Therapeutic drug monitoring is obviously a useful tool but is currently limited to the use of anti-TNFα. In this review paper, we provide overview and guidance on switching biologics in clinical practice, with the emphasis on the motivations for switching, the selection of the second-line biologic, as well as explanations on how and when to switch. |
